Document is current
Any future updates will be listed below
-
Authors
Damianos, John A.
Nehra, Avinash K.
Murray, Joseph A.
Loftus, Edward V. Jr.
Davis, John M. III
Nehra, Vandana
- License Information
-
More Information
Article History
Received: 17 March 2025
Accepted: 5 July 2025
First Online: 25 July 2025
Declarations
:
: Dr. Damianos receives clinical trial funding and consulting fees from ExeGi Pharma, as well as speakers bureau fees from i-Health. Dr. Davis has research support from Pfizer and has technology licensing agreements with Girihlet and Remission Medical. He has provisional U.S. patent application no. 63/243,933 entitled, “Methods and Materials for Assessing and Treating Arthritis,” which has been licensed to NLC Ventures. Dr. Loftus is a consultant for AbbVie, Alvotech, Amgen, Arena, Avalo, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion Healthcare, Eli Lilly, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iota Biosciences, Iterative Health, Janssen, Morphic, Ono, Protagonist, Sun, Surrozen, Takeda, and UCB. He has research support from AbbVie, AstraZeneca, Bristol-Myers Squibb, Celgene/Receptos, Janssen, Takeda, Theravance, and UCB. He is a shareowner of Exact Sciences. Dr. Murray has received research grants from Nexpep/ImmusanT, National Institutes of Health, Immunogenix, Takeda Pharmaceutical, Allakos, ProventionBio, Oberkotter Foundation, and 9 m, Inc.; contract (to institution) from Kanyos Bio (a wholly owned subsidiary of Anokion); and consultancy fees from Johnson and Johnson, Bristol-Myers Squibb, Intrexon Corporation, Dren Bio, Neoleukin, Reistone pharma, Immunic Therapeutics, Senda Biosciences, Brightseed Bio, Chugai Pharma, Alimentiv, Equillium, Ukko, Vial Health Technologies and has received royalties from Torax Medical and Evelo.
